Key result
SCH 48461 dose-dependently reduced LDL-C by 0.6% to 15.5% from baseline in patients with primary hypercholesterolemia, with doses from 6.25 to 400 mg showing greater reduction than placebo (p<=0.03).
Why the study?
Does SCH 48461 reduce LDL-C levels in patients with primary hypercholesterolemia?
Population
190 patients with primary hypercholesterolemia
Comparison
SCH 48461 once daily each morning for 8 weeks vs Placebo or lovastatin 40 mg once daily each…
Design
RCT, randomized, parallel-group, double-blind
Follow-up
8 weeks
Authors
Loading...
SCH 48461 lowers LDL-C in primary hypercholesterolemia; extends evidence for cholesterol absorption inhibition as a therapeutic approach.
RCT (n=190)
Double-blind
parallel-group
Yes
Does SCH 48461 reduce LDL-C levels in patients with primary hypercholesterolemia?
p-value: p=<= 0.03
SCH 48461, a cholesterol absorption inhibitor, demonstrates a dose-dependent, statistically significant reduction in LDL-C in patients with primary hypercholesterolemia.
Dujovne et al. (2001) conducted an RCT in primary hypercholesterolemia (n=190). SCH 48461 vs. Placebo and lovastatin 40 mg/day was evaluated on Percent reduction in low-density lipoprotein cholesterol (LDL-C) from baseline (p=<= 0.03). SCH 48461 dose-dependently reduced LDL-C by 0.6% to 15.5% from baseline in patients with primary hypercholesterolemia, with doses from 6.25 to 400 mg showing greater reduction than placebo (p<=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: